Unigene announces continuation of phase III study of oral calcitonin in osteoarthritis patients
Tuesday, July 27, 2010 18:00 IST Boonton, Jersey
Unigene Laboratories, Inc announced that Novartis and its license partner Nordic Bioscience have decided to continue the companies' two-year, phase-III study 2302